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D
uring the autoimmune response, when autoan-
tigens are presented in addition to signals in-
duced upon T-cell receptor engagement, T-cell
activation requires the engagement of their
costimulatory receptors by ligands on antigen-presenting
cells (APCs) (1–3). The number of known costimulatory
receptor/ligand pairs has grown signiﬁcantly over the last
decade (2,3), and it is now clear that costimulatory recep-
tors can deliver signals either enhancing or inhibiting
T-cell activation, thus determining the fate of the immune
response (4). Classically, costimulatory molecule ligands
were found on major histocompatibility complex (MHC)
class II–expressing cells (so-called “professional APCs”),
yet new data have demonstrated parenchymal expression
of costimulatory ligands (e.g., in pancreatic islets) (5), thus
providing a second level of immune response regulation in
situ (6).
Many players appear to have a role in the interaction
between the immune system and -cells: the classical
costimulatory molecule B7.1 (or CD80), a receptor ex-
pressed by APCs and parenchymal cells that engages the
T-cell ligand CD28 and thus activates the immune system
(9); programmed death receptor-1 (PD-1), an inhibitory
receptor induced on activated T-, B-, and myeloid cells;
and ﬁnally, the ligand for PD-1 (PD-L1 or B7-H1), which is
constitutively expressed in parenchymal organs (10–12).
Triggering negative signals through the interaction of PD-1
and PD-L1 could inhibit T-cell activation as well as the
migration of T-cells into peripheral tissues (10–13). In
NOD mice, islet PD-L1 expression has been shown to
protect syngeneic transplanted islets (NOD.SCID into hy-
perglycemic NOD) against recurrence of diabetes (5).
While PD-L1 inhibits pathogenic self-reactive CD4 T-cell–
mediated tissue destruction and effector cytokine produc-
tion in NOD mice, no data are available thus far in the
context of nonautoimmune strains (e.g., C57BL/6). More-
over, no data are currently available on the inhibitory
effect of PD-L1 on CD8 T-cells, which ostensibly are more
sensitive than CD4 T-cells to the inhibition induced by
PD-1/PD-L1 engagement (14).
In this issue of Diabetes, Rajasalu et al. (15) investigate
the interaction of costimulatory molecules (on -cells) and
their ligands (on CD8 T-cells) in a relatively new model of
experimental autoimmune diabetes (EAD). The authors
immunized C57BL/6 RIP-B7.1 mice (which constitutively
expressed B7.1 under the control of the insulin promoter)
with a plasmid-based DNA vaccine expressing an autoan-
tigen (preproinsulin [ppins]) to prime insulin-speciﬁc CD8
T-cells (16), inducing EAD in 90% of mice. Anti-CD8, but
not anti-CD4, antibody inhibited diabetes progression,
establishing that the effector phase of EAD depends on
diabetogenic CD8 T-cells. The role of CD8 T-cells was then
conﬁrmed by pathological analysis, which revealed a large
number of inﬁltrating CD8 T-cells in the pancreatic islets,
as well as by ex vivo assays, which demonstrate marked
production of -interferon (IFN-) from CD8 T-cells iso-
lated from ppins-primed mice when rechallenged with
autoantigen (17). When immunizing WT-B6 mice, EAD
incidence was relatively low, indicating the necessary role
of costimulatory/inhibitory signals in sensitizing -cells for
CD8 T-cell–mediated destruction.
To strengthen their hypothesis, a series of adoptive
transfer experiments were then performed. The authors
show that CD8 T-cells primed in WT-B6 mice can efﬁ-
ciently destroy -cells in vivo in an IFN-–dependent
manner, as suggested by the onset of diabetes in suble-
thally irradiated RIP-B7.1 mice once splenic CD8 T-cells
were adoptively transferred from primed WT-B6 mice.
Since B7.1 is not expressed normally on islet -cells and
PD-1/PD-L1 ligation can inhibit the B7.1/CD28 costimula-
tory pathway, the authors then investigated whether loss
of the inhibitory PD-1/PD-L1 signal has similar effects to
B7.1 constitutive knock-in. The authors thus abrogated
PD-L1 signaling either using a blocking monoclonal anti-
body or through gene targeting (by using PD-L1
/ mice),
rendering -cells susceptible to CD8 T-cell–mediated de-
struction and resulting in severe hyperglycemia.
By multiple bone marrow transplantation and chimeric
generation, the authors discovered that either the selective
deﬁciency of PD-L1 on -cells or the deﬁciency of PD-1 on
CD8 T-cells triggered CD8 T-cell–mediated EAD, suggest-
ing the importance of signal balance between the B7.1/
CD28 and PD-1/PD-L1 pathways in maintaining tolerance
toward -cells in the periphery.
The important take-home message and the article’s
strength is the description of how -cell inhibitory signals
and T-cells are attuned to maintain tolerance toward
autoantigen and the number of events that can interfere
with costimulatory cascades to actually break this toler-
ance. For instance, the priming of the immune system, the
upregulation of costimulatory molecules on -cells, or the
disruption of inhibitory signals on -cells or in the immune
system may all precipitate diabetes. Few weaknesses can
be highlighted in this research; however: 1) -cells do not
normally express B7.1, but events leading to B7.1 upregu-
lation (e.g., viruses, stresses, IFN- production, etc.) may
trigger autoimmune diabetes; 2) the proposed model is not
yet fully studied, and NOD mice remain the gold standard
for studies on autoimmune diabetes; and 3) other factors
have been shown to expand autoreactive T-cells once
transgenically overexpressed on -cells (e.g., heat shock
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the proposed pathway (18).
This new acquired knowledge may change the view of
how -cells and the immune system interact in autoim-
mune diabetes (Fig. 1A–C). Therefore, it is certainly time
to revisit examination of -cell function during the auto-
immune response, thereby assigning -cells a more proac-
tive role in controlling autoimmunity rather than viewing
them as bystanders waiting to be destroyed by autoreac-
tive CD4/CD8 T-cells (Fig. 1A–C) (7,8). Future directions
of this work may lead us to rethink -cells as active
players and as potential immunomodulatory tools in the
onset and therapy of autoimmune diabetes, respectively.
Possible therapeutic applications to halt the autoimmune
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FIG. 1. Model proposal of a more proactive -cell role in autoimmune response. A resting immune system is maintained by the delivery of
inhibitory signals to T-cells through negative costimulatory molecules expressed on -cells (A). B7.1 up-regulation promotes engagement of CD8
T-cells with -cells, thus triggering experimental autoimmune diabetes (B). In the absence of B7.1 on -cells, the deletion (or downregulation)
of PD-1 on CD8 T-cells or of PD-L1 on -cells may trigger experimental autoimmune diabetes (C). (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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inhibitory costimulatory signals (PD-L1) in the islet trans-
plantation setting, the use of small molecules able to signal
through inhibitory costimulatory receptors, or the discov-
ery of new agents capable of downregulating -cell sensi-
tization (in the type 1 diabetes prevention setting). -Cells
appear to step up and control the autoimmune response,
thus being more responsible for their fate and acting as
gatekeepers of the insulitic process, and this proposed
model may be used to cure or prevent type 1 diabetes.
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